Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 6Gastrointestinal 4Head & Neck 2Genitourinary 2Breast 2Sarcoma 1Other solid neoplasm 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Dynamic Contrast Enhanced Magnetic Resonance Imaging × Genitourinary × Clear all
NCT02312401 2026-01-29

Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Prostatic Neoplasms

NCT01221506 2020-03-26

Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡